CoreCap Advisors’s 4D Molecular Therapeutics FDMT Stock Holding History

CoreCap Advisors’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-82	Closed	-$457	–	3187
2024 Q4	$457	Buy	+82	New	+$643	﹤0.01%	2547

Other funds holding FDMT

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

CoreCap Advisors's FDMT Position: Q1 2025 in Review

CoreCap Advisors sold out of 4D Molecular Therapeutics (FDMT) in Q1 2025, closing a stake of 82 shares — an estimated $457 sold.

CoreCap Advisors first reported a position in FDMT in Q4 2024 and held it in 1 quarter. The position peaked at $457 in Q4 2024. 125 funds tracked by Wall St. Rank hold FDMT as of Q1 2025.

CoreCap Advisors reported no remaining 4D Molecular Therapeutics position as of Q1 2025 after selling out during the quarter.
CoreCap Advisors sold 82 4D Molecular Therapeutics shares in Q1 2025, an estimated $457.
CoreCap Advisors first reported a position in 4D Molecular Therapeutics in Q4 2024 and held it in 1 quarter.
CoreCap Advisors's 4D Molecular Therapeutics position peaked at $457 in Q4 2024.
125 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2025.

Based on CoreCap Advisors's 13F filing for Q1 2025, filed 9 May 2025.